MetaCap

Standard BioTools (LAB) vs 10x Genomics (TXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

10x Genomics (TXG) has outperformed Standard BioTools (LAB) over the past year, gaining 182.4% versus a loss of 54.3%. Over five years, TXG leads with a -65.2% price change compared with -86.5% for LAB. 10x Genomics is the larger company by market cap ($6.81 billion vs $249.1 million), about 27.4 times the size.

10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -87.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LAB-54.28%TXG+182.44%
+458%+186%-86%
Nov 21, 20251 yearNov 20, 2026
LAB-85.95%TXG-65.46%
+9%-45%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LAB versus TXG key metrics
MetricLABTXG
Share price$0.631$51.80
Market cap$249.11M$6.81B
1-day change+2.82%-9.72%
YTD return-50.70%+217.60%
1-year return-54.28%+182.44%
5-year return-86.55%-65.20%
Forward P/E—597.67
EPS (TTM)$-0.09$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.33M$642.82M
Revenue growth (YoY)-6.24%+5.25%
Net income (latest FY)$-74.90M$-43.54M
Gross margin49.86%69.05%
Operating margin-129.20%-9.49%
Net margin-87.77%-6.77%
52-week high$1.72$102.81
52-week low$0.39$15.18
Distance from 52-week high-63.31%-49.62%
Analyst consensusnonebuy
Avg. price target upside+113.95%+31.54%
Average volume1.16M3.36M
Shares outstanding394.79M121.46M
Employees3851,178
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • 10x Genomics is about 27.4 times larger than Standard BioTools by market value ($6.81B vs $249.11M).
  • TXG has outperformed LAB by 236.7 percentage points over the past year.
  • 10x Genomics is more profitable, keeping -6.8 cents of every revenue dollar as net income versus -87.8 cents for Standard BioTools.
  • 10x Genomics grew revenue faster in its latest fiscal year (+5.25% vs -6.24%).

About Standard BioTools

LAB stock →

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees

About 10x Genomics

TXG stock →

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees

LAB vs TXG FAQ

Which is bigger, Standard BioTools or 10x Genomics?

10x Genomics (TXG) is larger, with a market capitalization of $6.81B compared with $249.11M for Standard BioTools (LAB).

Which stock has performed better over the past year, LAB or TXG?

TXG returned +182.44% over the past 12 months, compared with -54.28% for LAB (price return, excluding dividends). Past performance does not predict future results.

Are Standard BioTools and 10x Genomics in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons